Boston Scientific Corp (BSX) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.

Total Cash From Operating Activities Chart for Boston Scientific Corp

Boston Scientific Corp (BSX) operating cash flow for FY2025 was USD 4.5B, a 32.0% change from FY2024. Boston Scientific Corp's operating cash flow grew from USD 29.6M in 1991 to USD 4.5B in 2025 (15217.6% over 34 years). Operating cash flow compound annual growth rate: 5-year CAGR of 24.6%, 10-year CAGR of 22.4%, 20-year CAGR of 8.4%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$71.45B
Implied Share Price
$49.30
Enterprise Value
$83.23B
Revenue (TTM)
$21.00B
EBITDA
$5.71B
Profit Margin
17.50%
Trailing P/E
19.33
Forward P/E
14.93
Price/Book (MRQ)
2.85
Price/Sales (TTM)
3.40
EV/EBITDA
14.76
EV/Revenue
3.96
Dividend Yield
—
Book Value
$17.23
Free Cash Flow (FY2025)
$3.66B
Free Cash Flow Yield
5.12%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.